Please login to the form below

Not currently logged in
Email:
Password:

chronic diseases

This page shows the latest chronic diseases news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

AstraZeneca’s push into genetic therapies has stepped up a gear, thanks to a collaboration with 4D Molecular Therapeutics on a new project in chronic lung disease. ... Last year, AZ also paid 25m upfront in a research deal with German biotech Ethris to

Latest news

More from news
Approximately 6 fully matching, plus 172 partially matching documents found.

Latest Intelligence

  • ‘How is your day?’ ‘How is your day?’

    Plasma protein therapies are biologic medicines – derived from human plasma or recombinant analogues (that treat bleeding disorders) – that treat a range of life-threatening, chronic and genetic diseases. ... These are: Primary Immunodeficiency

  • No incentive for a cure No incentive for a cure

    Type 1 diabetes, heart failure, HIV - all examples of diseases that have transitioned from fatal conditions to chronic diseases, thanks to the progress in modern medicine. ... The question is, are incremental improvements sustainable in the long-term,

  • The rise of real-world evidence The rise of real-world evidence

    Yet, RWE originally established itself in chronic diseases. “It can help differentiate you in a crowded space or, for more complex, chronic diseases, it can show that the benefits seen in

  • Significant figures Significant figures

    lung diseases demonstrated complete eradication compared to only 9% of patients on placebo. ... NTM is a rare progressive, destructive infection that’s normally found in addition to pulmonary diseases such as chronic obstructive pulmonary disease (COPD)

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

More from intelligence
Approximately 2 fully matching, plus 38 partially matching documents found.

Latest appointments

  • Kymab appoints its first chief medical officer Kymab appoints its first chief medical officer

    She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    Dr Zhou will lead the team's discovery and engineering activities on Chimeric Antigen Receptor in Treg cells ( CAR-Treg) for immunotherapy of severe chronic autoimmune and inflammatory diseases and organ

  • Sanofi’s US pharma head joins Synta as CEO Sanofi’s US pharma head joins Synta as CEO

    She now leads an emerging US-based biopharma focused on the development of small molecule drugs to treat patients with severe medical conditions, including cancer and chronic inflammatory diseases. “

  • Medgenics confirms appointment of Dr Marvin Garovoy

    The company's Biopump uses a patient's own tissue to continuously produce and deliver their protein therapy and, potentially, has applications in a range of chronic diseases, including diabetes, multiple

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Wearables and Healthcare

    Factors such as these, among others, have increased the prevalence of chronic diseases, which account for around 70% of the health service budget.[3, 4] To ensure the sustainability of the ... The outputs of this process are predictive algorithms that

  • Alzheimer’s disease: reviewing the immediate treatment horizon

    Alzheimer’ s disease: reviewing the immediate treatment horizon. Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease. With a

  • Alzheimer's: the numbers we cannot forget

    Alzheimer's: the numbers we cannot forget. In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the glimmers of light at the end of the

  • Don't you forget about me...

    What could this look like? Let's look at non-communicable chronic diseases, which currently contribute 86% of the deaths and 77% of the disease burden across Europe – and so are ... So, what can we do? Well, the groups most at risk from

  • Aubrey De Grey provides a summary of his goal of combating ageing

    He discusses the fact that many diseases including chronic cancer, are the result of ageing and that by tackling ageing of cells, we can address many of the issues associated with

More from PMHub
Approximately 4 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics